Studies in the clinic have demonstratedBIT225 treated isolated cells from HIV-1 infected patients show reduced HIV-1 release from CD14+ monocytesFollowing 10 days of monotherapy in HIV-1 infected patients, BIT225 can reduce viral copy numbers and inhibit replication in myeloid lineage cells (including dendritic cells)BIT225 may impact on macrophage associated immune activationBIT225 is able to cross the blood-brain barrier, with potential to treat HIV-associated neurocognitive disorder (HAND)
- Forums
- ASX - By Stock
- BIT
- Ann: BIT225 Phase 2 HIV Efficacy Trial Meets Primary Objectives
Ann: BIT225 Phase 2 HIV Efficacy Trial Meets Primary Objectives, page-6
-
- There are more pages in this discussion • 110 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BIT (ASX) to my watchlist
|
|||||
Last
2.7¢ |
Change
0.001(3.85%) |
Mkt cap ! $24.36M |
Open | High | Low | Value | Volume |
2.7¢ | 2.8¢ | 2.6¢ | $21.78K | 807.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 138461 | 2.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.7¢ | 194761 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 138461 | 0.026 |
10 | 880546 | 0.025 |
2 | 3373333 | 0.024 |
1 | 130000 | 0.023 |
4 | 825000 | 0.022 |
Price($) | Vol. | No. |
---|---|---|
0.027 | 194761 | 1 |
0.028 | 47808 | 2 |
0.029 | 260000 | 2 |
0.030 | 47636 | 2 |
0.031 | 159129 | 3 |
Last trade - 16.10pm 19/08/2024 (20 minute delay) ? |
Featured News
BIT (ASX) Chart |